Staging and Prognosis of Nasopharyngeal Cancer: The Time for Change Is Now
Menée à partir de données portant sur 4 914 patients atteints d'un carcinome rhinopharyngé (âge médian : 48,1 ans ; 74,3 % d'hommes), cette étude évalue la performance, du point de vue de la survie globale, de la neuvième version du système de stadification TNM de l'"American Joint Committee on Cancer" et de l'"Union for International Cancer Control"
Over the last several years, the prognosis for patients with nasopharyngeal cancer has improved due to therapeutic advances. As a result, the staging system has lagged behind, creating a discrepancy between expected and actual treatment outcomes. Given this incongruence, an updated staging system is warranted to accurately capture the successful change in patient survival. In JAMA Oncology, Pan et al present the American Joint Committee on Cancer (AJCC) version 9 TNM Staging System for nasopharyngeal carcinoma (NPC). They retrospectively analyzed tumor biological features and overall survival of 4914 patients from an international cohort diagnosed with NPC. Based on their results, they propose reclassification of stage I to III for localized disease, stage IV distant metastatic disease, while also adding radiological extranodal extension (ENE) as a criterion for N3.
JAMA Oncology , éditorial, 2023